Eidos Therapeutics, a clinical stage biopharmaceutical company, is generating buzz in the industry as it aims to address the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). With its focus on developing acoramidis, a potentially disease-modifying therapy for the treatment of ATTR, Eidos Therapeutics is poised to make a splash in the growing biotech space.
Eidos Therapeutics, Inc.'s ticker is EIDX
The company's shares trade on the NASDAQ stock exchange
They are based in San Francisco, California
There are 51-200 employees working at Eidos Therapeutics, Inc.
It is https://www.eidostx.com/
Eidos Therapeutics, Inc. is in the Healthcare sector
Eidos Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Eidos Therapeutics, Inc.'s industry peers: